Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
2,673 people get EXEL articles and Market Currents by email alert.
Get email alerts on EXEL »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exelixis: A Standout Pick For Upcoming ASCO WeekBrian L. Wilson • Thu, May 31, 2012
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
4 Biotech Stocks On The ClockStock Traders Daily • Tue, Feb 19 -
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Exelixis' CEO Discusses Q3 2012 Results - Earnings Call TranscriptWed, Nov 7, 2012
-
Exelixis' CEO Discusses Q2 2012 Results - Earnings Call TranscriptThu, Aug 2, 2012 • 3 Comments
-
Exelixis's CEO Discusses Q1 2012 Results - Earnings Call TranscriptThu, May 3, 2012
-
Exelixis' CEO Discusses Q4 2011 Results - Earnings Call TranscriptWed, Feb 8, 2012
-
Business Wire (Jun 5, 2013)
-
Business Wire (May 31, 2013)
-
Business Wire (May 15, 2013)
-
Business Wire (May 8, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (May 7, 2013)
-
Business Wire (Apr 17, 2013)
-
at CNBC.com (Apr 16, 2013)
-
Business Wire (Feb 25, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 21, 2013)
-
Business Wire (Feb 7, 2013)
-
Business Wire (Feb 6, 2013)
-
Business Wire (Jan 24, 2013)
-
Business Wire (Dec 13, 2012)
-
at MarketWatch.com (Nov 30, 2012)
-
at CNBC.com (Nov 30, 2012)
EXEL vs. ETF Alternatives
Company Description
BUSINESS
Overview
We are committed to discovering, developing and commercializing innovative therapies for the treatment of cancer and other serious diseases. Through our integrated drug discovery and development activities, we are building a portfolio of novel compounds that we believe... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 31, 8:43 AM Exelixis (EXEL) initiates a Phase 3 pivotal trial of cabozantinib (the tyrosine kinases inhibitor that is FDA approved for the treatment of metastatic medullary thyroid cancer) in patients with metastatic renal cell carcinoma. (PR) 2 Comments [Healthcare]
- Tuesday, May 7, 4:21 PM Exelixis (EXEL): Q1 EPS of -$0.24 beats by $0.05. Revenue of $9.7M beats by $4.37M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Tuesday, May 7, 12:10 AM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GA, GPOR, HTA, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
- Monday, May 6, 5:35 PM Notable earnings after Tuesday’s close: ANDE, ARAY, AWK, AXLL, BIO, BIOL, BMC, BWC, CA, CDXS, CHRW, CODI, DGI, DGIT, DIS, DVA, EA, ENPH, EXEL, GTEK, GA, GPOR, IAG, JAZZ, KGC, LYV, MAKO, MCEP, MCK, MDLZ, MITK, MRO, MYGN, NVTL, OAS, OCLR, OHI, ONXX, ORA, PRI, RBCN, SD, SGEN, SYMC, SYNC, TRIP, TWO, URS, VCLK, WBMD, WFM, WMB, WPZ, WTI, Z 1 Comment [Earnings]
-
Friday, February 22, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: EXEL +3%. DSLV +3%. BLT +2%. CY +2%. CZR +2%.
After-hours top losers: WETF -8%. SCLN -5%. MMSI -4%. ANF -3%. CHTR -3%. Comment! [On the Move] - Thursday, February 21, 4:24 PM Exelixis (EXEL): Q4 EPS of -$0.28 misses by $0.04. Revenue of $7.8M misses by $1.66M. Shares -1.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
- Thursday, February 21, 12:10 AM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD Comment! [Earnings]
- Wednesday, February 20, 5:35 PM Notable earnings after Thursday’s close: ACTG, AIG, ARUN, ATLS, BMRN, BV, CENX, CLGX, COG, CUBE, CYH, DRYS, EXEL, EXR, FIRE, FLS, FTR, GDI, HPQ, INT, INTU, ITMN, JWN, MRVL, NEM, NPSP, ONXX, PSA, SBAC, SWN, TS, WBMD 2 Comments [Earnings]
-
Thursday, January 10, 5:35 PM
After-hours top gainers, as of 5:15 p.m.: RPTP +6%. BGCP +4%. VECO +4%. EXEL +4%. MNST +3%.
After-hours top losers: KBR -8%. XRTX -5%. ABFS -5%. URBN -4%. QLTY -4%. Comment! [On the Move] - Friday, November 30, 2012, 10:57 AM Shares of Exelixis (EXEL -6.4%) are trading lower today following yesterday's post-session trading halt, despite receiving approval from both the FDA and the European Medicines Agency for cabozantinib, a treatment for a rare type of thyroid cancer. Part of the reason for the dip can possibly be attributed to the lack of information on the drug going into the decision, plus skittishness following an unexplained cancellation of the FDA's vote on cabozantinib's NDA earlier this month. Comment! [Healthcare, On the Move]
- Thursday, November 29, 2012, 4:18 PM The FDA has approved Exelixis' (EXEL) cabozantinib thyroid cancer drug. Shares are halted. (previous) Comment! [Healthcare, On the Move, Breaking News]
-
Friday, November 9, 2012, 5:45 PM
After-hours top gainers, as of 5:15 p.m.: MYRX +23.5%. NXTM +6.5%. BGCP +5.4%. IO +5.3%. MSCC +4.7%.
After-hours top losers: STSI -10.2%. PEGA -7.5%. ENR -7%. WG -6.7%. EXEL -6%. 1 Comment [On the Move] - Wednesday, November 7, 2012, 12:10 AM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Tuesday, November 6, 2012, 5:35 PM Notable earnings after Wednesday’s close: ARAY, ATO, ATVI, AWK, BONE, CBS, CLR, CODI, CPE, CPNO, CTL, CXO, ETE, ETP, EXEL, FTK, GMXR, GSS, HIMX, HNSN, ITMN, KGC, MAKO, MBI, MDLZ, MNST, MWE, NQ, OAS, ONTY, OSUR, PAAS, PANL, PRI, PRU, QCOM, SGEN, SLXP, SNTS, SRZ, SSRI, SXL, TCAP, TIE, TS, WFM Comment! [Earnings]
- Monday, August 6, 2012, 4:02 PM Shares of Exelixis (EXEL -13%) were hammered today after the biotech firm announced plans to hold back-to-back public offerings. It plans to offer, subject to market conditions, 20M common shares and an aggregate $225M of convertible senior subordinated notes due in 2019. Comment! [Healthcare, On the Move]
- Thursday, August 2, 2012, 5:07 PM Exelixis (EXEL): Q2 EPS of -$0.25 beats by $0.02. Revenue of $7.8B (-76% Y/Y) misses by $3.2B. (PR) Comment! [Earnings, Healthcare]
-
TruffelPig
$EXEL - this is the probably dumbest analysis I ever read on a biotech spec stock: http://bit.ly/XimHOl - View all 0 replies
-
- View all 1 replies
-
-
- View all 0 replies
-
BlackRook
$EXEL "off label" for men with very late stage, metastatic, and chemotherapy-resistant prostate cancer too.' http://bit.ly/YeLINU - View all 2 replies
-
Maria Auziliadora: that's pretty good thank's for the I see this one going higher -
-
- View all 1 replies
-
-
- View all 6 replies
-
-
-
BlackRook
$EXEL- MTC is a relatively small market. The scope in this trial scheduled to complete next month, is huge. http://1.usa.gov/TtVns9 - View all 1 replies
-
-
- View all 3 replies
-
Maria Auziliadora: I know it is rdiculous but big companies can buy this one out easily
-
-
- View all 0 replies
-
Chemistfrog
EXEL should start getting a lot of serious attention going into 11/29 PDUFA cabozantinib. Priority review.. $EXEL - View all 0 replies
LATEST REPLIES
-
- View all 1 replies
-
-
- View all 3 replies
-
Maria Auziliadora: I know it is rdiculous but big companies can buy this one out easily
-
-
BlackRook
$EXEL "off label" for men with very late stage, metastatic, and chemotherapy-resistant prostate cancer too.' http://bit.ly/YeLINU - View all 2 replies
-
Maria Auziliadora: that's pretty good thank's for the I see this one going higher
-
-
- View all 1 replies
-
-
- View all 6 replies
-
-
-
BlackRook
$EXEL- MTC is a relatively small market. The scope in this trial scheduled to complete next month, is huge. http://1.usa.gov/TtVns9 - View all 1 replies
-
-
- View all 3 replies
-
-
TruffelPig: EXEL will have a product soon on the market - GERN after xxxxxxxxx years Phase II again.........
-
- View all 1 replies
-
-
- View all 5 replies
-
-
-
- View all 2 replies
-
-
TruffelPig: Well, at least that way the dilution is out of the way :). Time to get long.
-
- View all 1 replies
-
-
TruffelPig
EXEL being whipped on secondary even though FDA review for MTC drug on Nov. 17 likely great! - View all 7 replies
-
TruffelPig: Hehehe, don't blame me if it doesn't work out. However, I think this will be a winner.
-
kevin1533: Haha ive been following this for a while. was waiting for an entry point
-
- View all 3 replies
-
-
-
- View all 1 replies
-
-
- View all 3 replies
-
Chemistfrog: CC is Tues, I bought in case they have good news about licensing or resuming their program I'll sell on spike. If no news at CC dump it..
-